Clinipace Worldwide Launches RSD Global Consulting
MORRISVILLE, NC, Aug. 03, 2017 (GLOBE NEWSWIRE) - Clinipace Worldwide, a global full-service clinical research organization (CRO), has launched a new regulatory and strategic development consultancy called RSD Global Consulting (RSDGC).
With more than 50 specialists, Clinipace RSD Global Consulting provides strategic consulting and regulatory support in the U.S., Europe, and Asia Pacific. RSDGC offers stage-specific solutions for all phases of development, from non-clinical and clinical, through to marketing applications and post-marketing support. The group also provides all aspects of pharmaceutical development support, including chemistry, manufacturing, and controls (CMC) strategy; dossier preparation; pre-approval inspection (PAI) preparation; GxP auditing for compliance in pre-clinical (GLP), clinical (GCP), manufacturing (GMP), medical/regulatory writing, strategic biostatistics and a quality assurance (QA) consultancy.
“Whatever the scale or complexity, RSD Global Consulting has the breadth and depth of technical, regulatory and quality expertise to take promising therapies from bench to bedside,” said Nikolas Burlew, who was recently appointed as Executive Vice President of RSD Global Consulting. “Our RSD Global Consulting team applies pragmatic approaches to the complex challenges of drug development, managing costs, quality, and deliverables to ensure that our clients’ goals are met.”
“We are delighted to launch this new consultancy in response to customer demand, especially amongst the early state biotech and pharma companies that we serve” said Clinipace President and CEO Jeff Williams. “We can work with companies of all sizes, from early-stage biotech firms, through to clinical stage and multinational. From traditional small molecules to advanced biologics, across the complete array of dosage forms and a wide range of therapeutic areas, we can help customers plan and advance their programs into the clinic, to regulatory approval and beyond.”
Media Contact
Sandra Parrish Woodlief
919-797-9480; swoodlief@clinipace.com
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
